XSXiaohe Su

Xiaohe Su

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaohe Su has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Hailong Liu

    Department of Urology Xinhua Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

    10 shared publications
  • Han Zeng

    Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China

    10 shared publications
  • Jiaxing Sun

    Department of Immunology School of Basic Medical Sciences Fudan University Shanghai China

    10 shared publications
  • Jiejie Xu

    National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China

    10 shared publications
  • Kaifeng Jin

    National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China

    10 shared publications
  • Le Xu

    Department of Urology Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

    10 shared publications

Latest Publications

  • Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma

    by Jiaxing Sun, Kaifeng Jin, Yawei Ding, Yuzhen Wu, Lingkai Zhang, Xiaohe Su, Jinming Shi, Zhaopei Liu, Han Zeng, Hailong Liu, et al.

    Background: Ki‐67 is routinely used in clinical practice to quantify proliferative activity, yet proliferation has not been incorporated into current molecular classification systems for urothelial carcinoma (UC). This work studies the tumor microenvironment (TME), therapeutic vulnerabilities, and clinical implications of the proliferative ecotype in UC. Methods: The authors assembled a multi‐cohort data set of 1431 UC patients from four institutional cohorts and five publicly available data sets with comprehensive clinicopathological annotations. Through an integrated multi‐omics framework coupled with experimental validation, they assessed how proliferative status shape lineage differentiation, clinical outcomes, treatment response, and TME architecture. Results: High Ki‐67 expression identified a proliferative ecotype associated with markedly worse prognosis but enhanced sensitivity to platinum‐based chemotherapy and PD‐1/PD‐L1 blockade. This ecotype displayed elevated tumor purity and tumor mutation burden, with characteristic genomic alterations including enrichment of TP53 , ERCC2 , and ATM/RB1/FANCC mutations and reduced 9p21.3 loss. The proliferative ecotype orchestrated an immune‐enriched TME dominated by CD8 + T cells and B cells. Functional analyses revealed that CD8 + T cells preferentially differentiated toward an exhausted state, and mechanistic interrogation identified a GDF‐15–TGFBR2 signaling axis through which epithelial cells modulate CD8 + T‐cell dysfunction. Conclusions: This study identifies a proliferative ecotype of UC that is orthogonal to classical luminal/basal ecotypes. Despite its adverse prognosis, this ecotype confers superior responsiveness to chemotherapy and immunotherapy and features a distinct genomic and immune ecosystem. These findings position proliferative status as a clinically actionable axis that may refine molecular classification and guide precision therapy in UC.

  • Natural killer cell infiltration elicits gender‐dependent dichotomous clinical outcomes in urothelial carcinoma

    by Lingkai Zhang, Zhaopei Liu, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Xiaohe Su, Kaifeng Jin, Han Zeng, Hailong Liu, Yuan Chang, et al.

    Background: Sex differences are a hallmark of urothelial carcinoma (UC), and profoundly influence disease progression and therapeutic outcomes. As critical effector immune cells with intrinsic sexual dimorphism, the contributions of natural killer (NK) cells to this clinical discrepancy remain incompletely understood. Methods: In this multicohort retrospective study of 885 patients with UC (671 males; 214 females), individuals were stratified into NK high and NK low subgroups on the basis of immunohistochemical or transcriptomic evaluation. The association of NK cells with clinical outcomes and the tumor immune microenvironment (TME) was systematically assessed across sexes. Single‐cell RNA sequencing and flow cytometry were deployed to decipher the functional state of NK cells. Results: Although NK cell infiltration levels were comparable between sexes, their clinical impact was markedly divergent: high NK infiltration conferred a significant survival advantage and superior response to both chemotherapy and immunotherapy exclusively in male patients. Further immune profiling revealed that NK high male patients exhibited a coordinated antitumor microenvironment, characterized by immunotype A features, tertiary lymphoid structure formation, and abundant infiltration of dendritic cells and effector T cells. Mechanistically, male‐derived NK cells maintained robust cytotoxic and inflammatory programs, whereas female‐derived NK cells were polarized toward a stressed, dysfunctional state with decidual‐like characteristics. Conclusions: Altogether, this study establishes NK cells as pivotal mediators of sex differences in UC. The stark contrast in NK cell phenotypes underscores a fundamental sexual dimorphism within the TME, which highlights the urgent need for sex‐tailored immunotherapy strategies.


  • Open Access

    Supplementary Table S1 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Details of immunohistochemistry antibodies.

  • Open Access

    Data from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Purpose:ARID1A, encoding a component of the switch/sucrose nonfermentable complex, is frequently mutated in urothelial carcinoma. However, its specific impacts on clinical outcomes and CD8+ T-cell functions in urothelial carcinoma remain poorly understood.Experimental Design:The clinical relevance of ARID1A loss and CD8+ T-cell infiltration was evaluated in three cohorts [Zhongshan Hospital, Fudan University (ZSHS), n = 135; Fudan University Shanghai Cancer Center (FUSCC), n = 118; and IMvigor210, n = 274]. Immune microenvironment profiling was performed via IHC in the ZSHS cohort and transcriptomics in the IMvigor210 cohort. The Shanghai-sequencing cohort (n = 134) provided genomic characterization of ARID1A-loss patients.Results:ARID1A loss did not affect overall survival and CD8+ T-cell infiltration in both ZSHS and FUSCC cohorts. Only in ARID1A-loss urothelial carcinoma, high infiltration of CD8+ T cells yielded favorable outcomes (ZSHS cohort, log-rank P = 0.010; FUSCC cohort, log-rank P = 0.015). Moreover, ARID1Aloss CD8high patients displayed improved survival following adjuvant chemotherapy (log-rank P = 0.015) and PD-1/PD-L1 blockade (log-rank P = 0.020). In ARID1A-loss urothelial carcinoma, the enhanced antitumor function of CD8+ T cells might be affected by tertiary lymphoid structures. Furthermore, ARID1Aloss CD8high patients exhibited an antitumor immune contexture characterized by decreased immune-suppressive cells such as DC-SIGN+ tumor-associated macrophages, PDPN+ cells, and TGF-β+ cells, as well as lower expression of checkpoints such as B7-H3 and B7-H4.Conclusions:The combination of ARID1A loss plus CD8+ T-cell infiltration indicated a favorable prognosis and responsiveness to both chemotherapy and immunotherapy. These findings provide valuable insights for developing novel therapeutic strategies and improving treatment stratification for urothelial carcinoma.

  • Open Access

    Supplementary Figure S2 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Representative IHC images of ARID1A and CD8+ T cells in UC.

  • Open Access

    Supplementary Figure S1 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Enrollment, clinicopathological features and inclusion criteria for ZSHS, FUSCC, and Shanghai-sequencing cohorts.

  • Open Access

    Supplementary Table S2 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Sources and details of the utilized gene signatures.

  • Open Access

    Supplementary Figure S4 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Association between ARID1A status and CD8+ T cell signature in the IMvigor210 cohort.

  • Open Access

    Supplementary Figure S3 from ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Association between ARID1A status and TMB in UC.

  • Open Access

    ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

    by Zhaopei Liu, Lingkai Zhang, Kaifeng Jin, Han Zeng, Xiaohe Su, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yu Zhu, et al.

    Purpose: ARID1A, encoding a component of the switch/sucrose nonfermentable complex, is frequently mutated in urothelial carcinoma. However, its specific impacts on clinical outcomes and CD8+ T-cell functions in urothelial carcinoma remain poorly understood. Experimental Design: The clinical relevance of ARID1A loss and CD8+ T-cell infiltration was evaluated in three cohorts [Zhongshan Hospital, Fudan University (ZSHS), n = 135; Fudan University Shanghai Cancer Center (FUSCC), n = 118; and IMvigor210, n = 274]. Immune microenvironment profiling was performed via IHC in the ZSHS cohort and transcriptomics in the IMvigor210 cohort. The Shanghai-sequencing cohort (n = 134) provided genomic characterization of ARID1A-loss patients. Results: ARID1A loss did not affect overall survival and CD8+ T-cell infiltration in both ZSHS and FUSCC cohorts. Only in ARID1A-loss urothelial carcinoma, high infiltration of CD8+ T cells yielded favorable outcomes (ZSHS cohort, log-rank P = 0.010; FUSCC cohort, log-rank P = 0.015). Moreover, ARID1Aloss CD8high patients displayed improved survival following adjuvant chemotherapy (log-rank P = 0.015) and PD-1/PD-L1 blockade (log-rank P = 0.020). In ARID1A-loss urothelial carcinoma, the enhanced antitumor function of CD8+ T cells might be affected by tertiary lymphoid structures. Furthermore, ARID1Aloss CD8high patients exhibited an antitumor immune contexture characterized by decreased immune-suppressive cells such as DC-SIGN+ tumor-associated macrophages, PDPN+ cells, and TGF-β+ cells, as well as lower expression of checkpoints such as B7-H3 and B7-H4. Conclusions: The combination of ARID1A loss plus CD8+ T-cell infiltration indicated a favorable prognosis and responsiveness to both chemotherapy and immunotherapy. These findings provide valuable insights for developing novel therapeutic strategies and improving treatment stratification for urothelial carcinoma.